In a report released today, Carter Gould from Barclays maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $52.00. The company's shares closed last Thursday at $53.40. According to TipRanks.com, Gould is a 3-star analyst with an average return of 3.8% and a 48.6% success rate. Gould covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Bristol Myers. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $57.33 average price target, representing an 8.3% upside.
https://www.tipranks.com/news/blurbs/pfizer-pfe-receives-a-hold-from-barclays-3?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
過去 株価チャート
から 8 2022 まで 10 2022 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 10 2021 まで 10 2022 Pfizerのチャートをもっと見るにはこちらをクリック